

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarci⦠read more
Healthcare
Biotechnology
15 years
USD
Exclusive to Premium users
$2.82
Price+4.45%
$0.12
$12.271m
Small
-
Premium
Premium
-
EBITDA Margin-117.8%
Net Profit Margin-3.6%
Free Cash Flow Margin-
EBITDA Margin-117.8%
Net Profit Margin-3.6%
Free Cash Flow Margin$1.403m
-40.4%
1y CAGR+154.2%
3y CAGR+115.6%
5y CAGR-$8.892m
+15.2%
1y CAGR-14.3%
3y CAGR-8.8%
5y CAGR-$2.12
-1941.7%
1y CAGR-650.1%
3y CAGR-482.2%
5y CAGR$20.835m
$38.797m
Assets$17.962m
Liabilities$9.070m
Debt23.4%
2.4x
Debt to EBITDA-$7.823m
+51.7%
1y CAGR-8.8%
3y CAGR-9.6%
5y CAGR